کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2124393 1547224 2009 15 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Targeted therapies in the treatment of advanced/metastatic NSCLC
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Targeted therapies in the treatment of advanced/metastatic NSCLC
چکیده انگلیسی

The treatment of advanced non-small cell lung cancer (NSCLC) has evolved substantially during the last years. Chemotherapy remains the cornerstone of treatment and prolongs survival with a positive impact on quality of life. However, we seem to have reached a plateau of activity in the treatment of NSCLC. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets has improved the outcome in selected patients with advanced NSCLC. Furthermore, the use of erlotinib and gefitinib is an alternative for second line treatment. Advances in our understanding of molecular biology of cancer and mechanisms of tumourigenesis have further enabled the discovery of several potential molecular targets and development of novel ‘targeted therapies’. The purpose of this study is to review current data on the role of targeted therapies in the treatment of advanced NSCLC.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 45, Issue 14, September 2009, Pages 2473–2487
نویسندگان
, , , , , , , ,